|
rs121913377
|
|
melanoma
|
TT |
0.800 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
rs121913377
|
|
melanoma
|
AT |
0.800 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
rs121913377
|
|
melanoma
|
TT |
0.800 |
GeneticVariation
|
CLINVAR |
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
|
24508103 |
2014 |
|
rs121913377
|
|
melanoma
|
TT |
0.800 |
GeneticVariation
|
CLINVAR |
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
|
23918947 |
2013 |
|
rs121913377
|
|
melanoma
|
AT |
0.800 |
CausalMutation
|
CLINVAR |
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
|
22972589 |
2013 |
|
rs121913377
|
|
melanoma
|
AT |
0.800 |
CausalMutation
|
CLINVAR |
Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations.
|
23317446 |
2013 |
|
rs121913377
|
|
melanoma
|
AT |
0.800 |
CausalMutation
|
CLINVAR |
Improved survival with MEK inhibition in BRAF-mutated melanoma.
|
22663011 |
2012 |
|
rs121913377
|
|
melanoma
|
AT |
0.800 |
CausalMutation
|
CLINVAR |
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
|
22805292 |
2012 |
|
rs121913377
|
|
melanoma
|
AT |
0.800 |
CausalMutation
|
CLINVAR |
Efficacy at the recommended phase 2 dose was studied in patients with BRAF-mutant tumours, including those with non-Val600Glu mutations, in three cohorts: metastatic melanoma, melanoma with untreated brain metastases, and non-melanoma solid tumours.
|
22608338 |
2012 |
|
rs121913377
|
|
melanoma
|
AT |
0.800 |
CausalMutation
|
CLINVAR |
Patients aged 18 years or older with previously untreated, stage IV or unresectable stage III BRAF(V600E) mutation-positive melanoma were randomly assigned (3:1) to receive dabrafenib (150 mg twice daily, orally) or dacarbazine (1000 mg/m(2) intravenously every 3 weeks).
|
22735384 |
2012 |
|
rs121913377
|
|
melanoma
|
AT |
0.800 |
CausalMutation
|
CLINVAR |
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
|
23020132 |
2012 |
|
rs121913377
|
|
melanoma
|
AT |
0.800 |
CausalMutation
|
CLINVAR |
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
|
22356324 |
2012 |
|
rs121913377
|
|
melanoma
|
TT |
0.800 |
GeneticVariation
|
CLINVAR |
Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma.
|
23031422 |
2012 |
|
rs121913377
|
|
melanoma
|
AT |
0.800 |
CausalMutation
|
CLINVAR |
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
|
22048237 |
2012 |
|
rs121913377
|
|
melanoma
|
AT |
0.800 |
CausalMutation
|
CLINVAR |
Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.
|
21639808 |
2011 |
|
rs121913377
|
|
melanoma
|
TT |
0.800 |
GeneticVariation
|
CLINVAR |
Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.
|
21639808 |
2011 |
|
rs121913377
|
|
melanoma
|
AT |
0.800 |
CausalMutation
|
CLINVAR |
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.
|
20630094 |
2010 |
|
rs121913377
|
|
melanoma
|
AT |
0.800 |
CausalMutation
|
CLINVAR |
In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.
|
20818844 |
2010 |
|
rs121913377
|
|
melanoma
|
AT |
0.800 |
CausalMutation
|
CLINVAR |
Our findings offer evidence of the potent antitumor activity of RG7204 against melanomas harboring the mutant BRAF(V600E) gene.
|
20551065 |
2010 |
|
rs121913377
|
|
melanoma
|
AT |
0.800 |
CausalMutation
|
CLINVAR |
Determinants of BRAF mutations in primary melanomas.
|
14679157 |
2003 |
|
rs121913377
|
|
melanoma
|
AT |
0.800 |
CausalMutation
|
CLINVAR |
Mutations of the BRAF gene in human cancer.
|
12068308 |
2002 |